{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:50:10Z","timestamp":1788893410473,"version":"build-2803163510"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000098","name":"Stem Cell Network","doi-asserted-by":"publisher","award":["20160906"],"award-info":[{"award-number":["20160906"]}],"id":[{"id":"10.13039\/501100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mesenchymal stromal cells (MSCs) have the capacity to self-renew and exert immunomodulatory and paracrine effects. Our previously published systematic review of 55 randomized controlled trials (RCTs) of all MSC sources found an overall favorable safety profile for MSCs aside from more frequent fever in the MSC group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Umbilical cord MSCs (UC-MSCs) possess potential biological and economic advantages over other MSC sources. Since several UC-MSC RCTs have been recently published in a heterogenous group of disorders, we performed a systematic review to specifically examine the safety profile of adult UC-MSC RCTs, while also providing quantitative syntheses (meta-analyses) of prespecified adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was performed up to August 2025. RCTs were identified that compared intravascular delivery of UC-MSCs in adults to a control group. The primary outcome was safety categorized by the following prespecified adverse events with potential relevance to UC-MSCs: (1) fever and (2) non-fever acute infusional toxicity within 24\u2009hours of study product administration, (3) infection, (4) death, (5) malignancy\/ectopic tissue formation, (6) thrombotic\/thromboembolic events, and (7) mycotic aneurysms. Prespecified adverse events were pooled and meta-analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 9160 studies were screened and 42 UC-MSC RCTs (n\u2009=\u20092280 patients) were included. UC-MSCs were associated with increased risk for fever (relative risk [RR] =2.34, 95% confidence interval [CI] =1.02-5.35). None of the other prespecified adverse events were associated with signals for harm. No included trials were stopped early due to safety concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>UC-MSC therapy appears safe for study in heterogeneous patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/stcltm\/szag029","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:53:53Z","timestamp":1773838433000},"source":"Crossref","is-referenced-by-count":2,"title":["Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8695-9884","authenticated-orcid":false,"given":"Christine","family":"Hum","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute , Ottawa, ON, K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Poliwoda","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa , Ottawa, ON, K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Lalu","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute , Ottawa, ON, K1H 8L6,","place":["Canada"]},{"name":"Regenerative Medicine Program, Ottawa Hospital Research Institute , Ottawa, ON, K1H 8L6,","place":["Canada"]},{"name":"Department of Cell and Molecular Medicine, University of Ottawa , Ottawa, ON, K1H 8L6,","place":["Canada"]},{"name":"Department of Anesthesiology and Pain Medicine, University of Ottawa, The Ottawa Hospital , Ottawa, ON, K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan J","family":"Stewart","sequence":"additional","affiliation":[{"name":"Regenerative Medicine Program, Ottawa Hospital Research Institute , Ottawa, ON, K1H 8L6,","place":["Canada"]},{"name":"Department of Cell and Molecular Medicine, University of Ottawa , Ottawa, ON, K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley H J","family":"Mei","sequence":"additional","affiliation":[{"name":"Regenerative Medicine Program, Ottawa Hospital Research Institute , Ottawa, ON, K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R","family":"Walley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Centre for Heart Lung Innovation, University of British Columbia , Vancouver, BC, V6Z 1Y6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7902-6291","authenticated-orcid":false,"given":"John","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Surgery (Critical Care), St. Michael\u2019s Hospital, University of Toronto , Toronto, ON, M5T 1P5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher A","family":"Mendelson","sequence":"additional","affiliation":[{"name":"Section of Critical Care Medicine, Department of Medicine, Rady Faculty of Health Sciences, University of Manitoba , Winnipeg, MB, R3E 3P5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A","family":"Fergusson","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute , Ottawa, ON, K1H 8L6,","place":["Canada"]},{"name":"Faculty of Medicine, University of Ottawa , Ottawa, ON, K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"English","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute , Ottawa, ON, K1H 8L6,","place":["Canada"]},{"name":"Department of Medicine (Critical Care), The Ottawa Hospital, Ottawa Hospital Research Institute, Centre for Transfusion and Critical Care Research , Ottawa, ON, K1H 8L6,","place":["Canada"]},{"name":"Department of Medicine (Division of Critical Care), University of Ottawa , Ottawa, ON, K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent W","family":"Winston","sequence":"additional","affiliation":[{"name":"Department of Critical Care, Medicine, and Biochemistry and Microbiology, University of Calgary , Calgary, AB, T2N 1N4,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Granton","sequence":"additional","affiliation":[{"name":"Department of Medicine (Critical Care), University of Toronto , Toronto, ON, M4N 3M5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia C","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Keenan Research Centre for Biomedical Science and Interdepartmental Division of Critical Care, St. Michael\u2019s Hospital, University of Toronto , Toronto, ON, M5B 1W8,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josee","family":"Champagne","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute , Ottawa, ON, K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauralyn","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute , Ottawa, ON, K1H 8L6,","place":["Canada"]},{"name":"Department of Medicine (Critical Care), The Ottawa Hospital, Ottawa Hospital Research Institute, Centre for Transfusion and Critical Care Research , Ottawa, ON, K1H 8L6,","place":["Canada"]},{"name":"Department of Medicine (Division of Critical Care), University of Ottawa , Ottawa, ON, K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2026060504151768500_szag029-B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3727\/096368910X","article-title":"Mesenchymal stem cells","volume":"20","author":"Ding","year":"2011","journal-title":"Cell Transplant"},{"key":"2026060504151768500_szag029-B2","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.intimp.2010.06.019","article-title":"The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy","volume":"10","author":"Hoogduijn","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"2026060504151768500_szag029-B3","doi-asserted-by":"publisher","first-page":"e2001689","DOI":"10.1002\/adhm.202001689","article-title":"Effects of mesenchymal stem cell-derived paracrine signals and their delivery strategies","volume":"10","author":"Chang","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"2026060504151768500_szag029-B4","doi-asserted-by":"publisher","first-page":"18078","DOI":"10.1038\/s41598-019-54462-x","article-title":"Thawed mesenchymal stem cell product shows comparable immunomodulatory potency to cultured cells In vitro and in polymicrobial septic animals","volume":"9","author":"Tan","year":"2019","journal-title":"Sci Rep"},{"key":"2026060504151768500_szag029-B5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s13287-021-02609-x","article-title":"The safety of MSC therapy over the past 15 years: a meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2026060504151768500_szag029-B6","doi-asserted-by":"publisher","first-page":"637725","DOI":"10.3389\/fcell.2021.637725","article-title":"Immunomodulatory properties of mesenchymal stromal cells: an update","volume":"9","author":"M\u00fcller","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026060504151768500_szag029-B7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.molmed.2018.12.006","article-title":"Intravascular mesenchymal stromal\/stem cell therapy product diversification: time for new clinical guidelines","volume":"25","author":"Moll","year":"2019","journal-title":"Trends Mol Med"},{"key":"2026060504151768500_szag029-B8","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/stem.2891","article-title":"Intravenous infusion of human adipose mesenchymal stem cells modifies the host response to lipopolysaccharide in humans: a randomized, single-blind, parallel group, placebo controlled trial","volume":"36","author":"Perlee","year":"2018","journal-title":"Stem Cells (1981)"},{"key":"2026060504151768500_szag029-B9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1089\/scd.2015.0329","article-title":"Effects of freeze\u2013thawing and intravenous infusion on mesenchymal stromal cell gene expression","volume":"25","author":"Hoogduijn","year":"2016","journal-title":"Stem Cells Dev"},{"key":"2026060504151768500_szag029-B10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4161\/cam.20875","article-title":"Mesenchymal stem cells in tumor development: emerging roles and concepts","volume":"6","author":"Cuiffo","year":"2012","journal-title":"Cell Adh Migr"},{"key":"2026060504151768500_szag029-B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-017-0597-8","article-title":"Mesenchymal stem cells: key players in cancer progression","volume":"16","author":"Ridge","year":"2017","journal-title":"Mol Cancer"},{"key":"2026060504151768500_szag029-B12","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.eclinm.2019.100249","article-title":"Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis","volume":"19","author":"Thompson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026060504151768500_szag029-B13","doi-asserted-by":"publisher","first-page":"1006295","DOI":"10.3389\/fcell.2022.1006295","article-title":"Umbilical cord mesenchymal stromal cells\u2014from bench to bedside","volume":"10","author":"Chetty","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2026060504151768500_szag029-B14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13287-021-02222-y","article-title":"Human umbilical cord-derived mesenchymal stem\/stromal cells: a promising candidate for the development of advanced therapy medicinal products","volume":"12","author":"Mebarki","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2026060504151768500_szag029-B15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","article-title":"Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential","volume":"41","author":"Song","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"2026060504151768500_szag029-B16","doi-asserted-by":"publisher","first-page":"923286","DOI":"10.3389\/fimmu.2022.923286","article-title":"Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: a systematic review and meta-analysis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"2026060504151768500_szag029-B17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13287-023-03286-8","article-title":"Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: a meta-analysis of randomized controlled trials","volume":"14","author":"Liu","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"2026060504151768500_szag029-B18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/jfb16030084","article-title":"Treatment of knee osteoarthritis and chondral injury with umbilical cord\/Wharton\u2019s jelly-derived mesenchymal stem cells: a systematic review of safety and efficacy","volume":"16","author":"Ishak-Samrin","year":"2025","journal-title":"J Funct Biomater"},{"key":"2026060504151768500_szag029-B19","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"key":"2026060504151768500_szag029-B20","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5.","author":"Deeks","year":"2024"},{"key":"2026060504151768500_szag029-B21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"key":"2026060504151768500_szag029-B22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"2026060504151768500_szag029-B23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"key":"2026060504151768500_szag029-B24","author":"Higgins","year":"2019"},{"key":"2026060504151768500_szag029-B25","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCRESAHA.117.310712","article-title":"Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1\/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy])","volume":"121","author":"Bartolucci","year":"2017","journal-title":"Circ Res"},{"key":"2026060504151768500_szag029-B26","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00125-023-05934-3","article-title":"Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a phase I\/II randomised double-blind placebo-controlled trial","volume":"66","author":"Carlsson","year":"2023","journal-title":"Diabetologia"},{"key":"2026060504151768500_szag029-B27","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","article-title":"A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis","volume":"76","author":"Deng","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026060504151768500_szag029-B28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/sctm.21-0046","article-title":"Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: a randomized controlled trial","volume":"10","author":"Dilogo","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"2026060504151768500_szag029-B29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1089\/scd.2021.0015","article-title":"Human umbilical cord mesenchymal stromal cell treatment of severe COVID-19 patients: a 3-month follow-up study following hospital discharge","volume":"30","author":"Feng","year":"2021","journal-title":"Stem Cells Dev"},{"key":"2026060504151768500_szag029-B30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12916-024-03275-5","article-title":"Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial","volume":"22","author":"Fu","year":"2024","journal-title":"BMC Med"},{"key":"2026060504151768500_szag029-B31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12916-015-0399-z","article-title":"Intracoronary infusion of Wharton\u2019s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial","volume":"13","author":"Gao","year":"2015","journal-title":"BMC Med"},{"key":"2026060504151768500_szag029-B32","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","article-title":"Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation","volume":"34","author":"Gao","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026060504151768500_szag029-B33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1164\/rccm.202302-0297OC","article-title":"Repair of acute respiratory distress syndrome in COVID-19 by stromal cells (REALIST-COVID trial) a multicenter, randomized, controlled clinical trial","volume":"208","author":"Gorman","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026060504151768500_szag029-B34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1507\/endocrj.ej12-0343","article-title":"Long term effects of the implantation of Wharton\u2019s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus","volume":"60","author":"Hu","year":"2013","journal-title":"Endocr J"},{"key":"2026060504151768500_szag029-B35","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.3892\/etm.2016.3724","article-title":"Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis","volume":"12","author":"Hu","year":"2016","journal-title":"Exp Ther Med"},{"key":"2026060504151768500_szag029-B36","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3892\/etm.2016.3544","article-title":"Long term effect and safety of Wharton\u2019s jelly-derived mesenchymal stem cells on type 2 diabetes","volume":"12","author":"Hu","year":"2016","journal-title":"Exp Ther Med"},{"key":"2026060504151768500_szag029-B37","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","article-title":"Mesenchymal stem cells for prophylaxis of chronic graft-vs-host disease after haploidentical hematopoietic stem cell transplant: an open-label randomized clinical trial","volume":"10","author":"Huang","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026060504151768500_szag029-B38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1186\/s12916-024-03782-5","article-title":"Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial","volume":"22","author":"Jiang","year":"2024","journal-title":"BMC Med"},{"key":"2026060504151768500_szag029-B39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13287-022-02920-1","article-title":"Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial","volume":"13","author":"Kaffash Farkhad","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"2026060504151768500_szag029-B40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.18502\/ijaai.v21i6.11530","article-title":"Specific clinical and immunological changes following mesenchymal stem cell transplantation in COVID-19\u2013induced acute respiratory distress syndrome patients: a phase-I clinical trial","volume":"21","author":"Kaffash Farkhad","year":"2022","journal-title":"Iran J Allergy, Asthma Immunol"},{"key":"2026060504151768500_szag029-B41","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/sctm.20-0472","article-title":"Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1\/2a, randomized controlled trial","volume":"10","author":"Lanzoni","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"2026060504151768500_szag029-B42","doi-asserted-by":"publisher","first-page":"104600","DOI":"10.1016\/j.ebiom.2023.104600","article-title":"Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial","volume":"92","author":"Li","year":"2023","journal-title":"EBioMedicine"},{"key":"2026060504151768500_szag029-B43","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.12998\/wjcc.v11.i21.5083","article-title":"Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: a phase 2 clinical trial","volume":"11","author":"Lian","year":"2023","journal-title":"World J Clin Cases"},{"key":"2026060504151768500_szag029-B44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13054-022-03930-4","article-title":"Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial","volume":"26","author":"Monsel","year":"2022","journal-title":"Crit Care"},{"key":"2026060504151768500_szag029-B45","doi-asserted-by":"publisher","first-page":"1224865","DOI":"10.3389\/fmed.2023.1224865","article-title":"Efficacy of Wharton Jelly mesenchymal stromal cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial","volume":"10","author":"Pochon","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026060504151768500_szag029-B46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13287-022-02796-1","article-title":"Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial","volume":"13","author":"Rebelatto","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"2026060504151768500_szag029-B47","doi-asserted-by":"publisher","first-page":"725","DOI":"10.5966\/sctm.2012-0034","article-title":"Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients","volume":"1","author":"Shi","year":"2012","journal-title":"Stem Cells Transl Med"},{"key":"2026060504151768500_szag029-B48","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/sctm.17-0134","article-title":"A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection","volume":"6","author":"Shi","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"2026060504151768500_szag029-B49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13287-022-02972-3","article-title":"One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment","volume":"13","author":"Shi","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"2026060504151768500_szag029-B50","doi-asserted-by":"publisher","first-page":"103789","DOI":"10.1016\/j.ebiom.2021.103789","article-title":"Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial","volume":"75","author":"Shi","year":"2022","journal-title":"EBioMedicine"},{"key":"2026060504151768500_szag029-B51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","article-title":"Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"6","author":"Shi","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026060504151768500_szag029-B52","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s12072-021-10199-2","article-title":"Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial","volume":"15","author":"Shi","year":"2021","journal-title":"Hepatol Int"},{"key":"2026060504151768500_szag029-B53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13287-020-01875-5","article-title":"Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells","volume":"11","author":"Shu","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"2026060504151768500_szag029-B54","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13287-024-03729-w","article-title":"Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of life","volume":"15","author":"Sitbon","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"2026060504151768500_szag029-B55","doi-asserted-by":"publisher","first-page":"12520","DOI":"10.1038\/s41598-023-39268-2","article-title":"Effectiveness and safety of normoxic allogenic umbilical cord mesenchymal stem cells administered as adjunctive treatment in patients with severe COVID-19","volume":"13","author":"Soetjahjo","year":"2023","journal-title":"Sci Rep"},{"key":"2026060504151768500_szag029-B56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12967-018-1422-x","article-title":"Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial","volume":"16","author":"Sun","year":"2018","journal-title":"J Transl Med"},{"key":"2026060504151768500_szag029-B57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-021-00607-2","article-title":"Human umbilical cord mesenchymal stem cell transfusion in immune non-responders with AIDS: a multicenter randomized controlled trial","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026060504151768500_szag029-B58","first-page":"3241","article-title":"Therapeutic effects of human umbilical cord mesenchymal stem cells transplantation on hypoxic ischemic encephalopathy","volume":"8","author":"Xie","year":"2016","journal-title":"Am J Transl Res"},{"key":"2026060504151768500_szag029-B59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12967-018-1541-4","article-title":"Serum IFN-\u03b3 levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis","volume":"16","author":"Yang","year":"2018","journal-title":"J Transl Med"},{"key":"2026060504151768500_szag029-B60","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO-24-02119","article-title":"Sequential infusion of mesenchymal stem cell for graft-versus-host disease prevention in haploidentical hematopoietic stem cell transplantation: an open-label, multicenter, randomized controlled clinical trial","volume":"43","author":"Yao","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026060504151768500_szag029-B61","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13287-025-04148-1","article-title":"Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Yuan","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"2026060504151768500_szag029-B62","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/QAD.0b013e32835fab77","article-title":"Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients","volume":"27","author":"Zhang","year":"2013","journal-title":"AIDS"},{"key":"2026060504151768500_szag029-B63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5009\/gnl17035","article-title":"Umbilical cord mesenchymal stem cell treatment for Crohn\u2019s disease: a randomized controlled clinical trial","volume":"12","author":"Zhang","year":"2018","journal-title":"Gut Liver"},{"key":"2026060504151768500_szag029-B64","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.4238\/2015.April.10.11","article-title":"Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure","volume":"14","author":"Zhao","year":"2015","journal-title":"Genet Mol Res"},{"key":"2026060504151768500_szag029-B65","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41422-021-00573-y","article-title":"Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms","volume":"31","author":"Zhu","year":"2021","journal-title":"Cell Res"},{"key":"2026060504151768500_szag029-B66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13287-024-03707-2","article-title":"Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I\/II randomized, double-blind, placebo-controlled study","volume":"15","author":"Zhu","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"2026060504151768500_szag029-B67","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jcyt.2024.10.008","article-title":"Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeutics","volume":"27","author":"Renesme","year":"2025","journal-title":"Cytotherapy"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/6\/szag029\/68479164\/szag029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/6\/szag029\/68479164\/szag029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:15:24Z","timestamp":1780647324000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/doi\/10.1093\/stcltm\/szag029\/8702822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szag029","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,18]]},"article-number":"szag029"}}